Autoimmune disease risk may differ by menopausal hormone therapy formulation
Progestogen, when used in hormone therapy, is recognized for its benefits in protecting the uterus. A new study suggests that its addition limits the increased risk of composite autoimmune disease associated with estrogen-only therapy. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego, Oct. 20–24, 2026.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
